EUVIMEDEUVIMED entdecken
Open Access

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels

Lingzi Yang, Haoran Chi, Yifan Zhang, Dongmei Wu, Yang Hu, Jianhe Guo, Yunsen He, Jinhua Fan, Keyi Lv, Feifei Cheng, Nong Xiao, Qiongling Peng und 5 weitere

Movement Disorders · 2026

DOI: 10.1002/mds.70248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2026. Verfasst von Lingzi Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' He…. Hauptthemen laut MEDLINE: Spastin, Spastic Paraplegia, Hereditary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key R&D Program of China, National Key Research and Development Program of China, Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SPG4, the most common hereditary spastic paraplegia caused by SPAST variants, exhibits extreme age‐at‐onset variability, indicative of uncharacterized genetic modifiers. The GJA1 R148Q variant (linked to oculodentodigital dysplasia) may modulate SPG4 pathogenesis, yet its underlying molecular mechanism remains undefined.

Objective

We investigated the molecular mechanism by which GJA1 R148Q accelerates early SPG4 onset in a proband with dual SPAST and GJA1 variants, and validated its function as a disease modifier for SPG4.

Methods

We performed comprehensive clinical phenotyping, segregation analysis, coimmunoprecipitation, ubiquitination analyses, CRISPR‐mediated correction in patient induced pluripotent stem cell2013derived organoids, and a targeted deubiquitinase screen.

Results

The GJA1 R148Q enhanced the physical interaction between SPASTIN and GJA1, accelerated the degradation of deubiquitinase valosin‐containing protein interacting protein 1 (VCPIP1), and thereby reduced SPASTIN levels. CRISPR‐based reversion of the R148Q restored SPASTIN levels and rescued microtubule‐severing function. Notably, maternal relatives carrying the GJA1 R148Q allele alone exhibited no neurological abnormalities.

Conclusions

The GJA1 R148Q variant, although non‐neurological in isolation, acts as a disease modifier that precipitates SPG4 by exacerbating SPASTIN haploinsufficiency through destabilization of VCPIP1, positioning GJA1‐VCPIP1‐SPASTIN signaling as a potential therapeutic axis for SPG4 treatment. © 2026 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SpastinSpastic Paraplegia, HereditaryHumansValosin Containing ProteinMaleFemaleAge of Onset

Substanzen

SpastinSPAST protein, humanVCP protein, humanValosin Containing Protein

Autor:innen und Institutionen

  • Department of Rehabilitation, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Devel…
  • Department of Neurology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
  • Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Key Laboratory of Major Brain Disease and Aging Research (Ministry of Education), Chongqing Medical University, Chongqing, China.
  • Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Neurosurgery, Sichuan Lansheng Brain Hospital & Shanghai Lansheng Brain Hospital Investment Co., Ltd, Chengdu, China.

ORCID-Profile: Tongfei Liu

Förderung

  • National Key R&D Program of China
  • National Key Research and Development Program of China
  • Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission
  • National Natural Science Foundation of China
  • Lingang Laboratory
  • Jiangxi Provincial Key Laboratory of Birth Defect for Prevention and Control
  • Youth Innovation in Future Medicine

Zitieren

APA

Yang, L., Chi, H., Zhang, Y., Wu, D., Hu, Y., Guo, J., He, Y., Fan, J., Lv, K., Cheng, F., Xiao, N., Peng, Q., Dong, Y., Wang, L., Wu, B., Zhong, M., & Liu, T. (2026). A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels. Movement Disorders. https://doi.org/10.1002/mds.70248

Vancouver

Yang L, Chi H, Zhang Y, Wu D, Hu Y, Guo J, et al. A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels. Movement Disorders. 2026. doi:10.1002/mds.70248

BibTeX
@article{Yang2026,
  author = {Yang, Lingzi and Chi, Haoran and Zhang, Yifan and Wu, Dongmei and Hu, Yang and Guo, Jianhe and He, Yunsen and Fan, Jinhua and Lv, Keyi and Cheng, Feifei and Xiao, Nong and Peng, Qiongling and Dong, Yanling and Wang, Longlun and Wu, Bo and Zhong, Min and Liu, Tongfei},
  title = {A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70248}
}
Kostenlos starten →